Drug Profile
OCT-B201
Alternative Names: BT-201Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Oscotec
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Osteoarthritis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Osteoarthritis in South Korea (PO)